Display options
Cite
Shenker RF, Hughes RT, McTyre ER, et al. Potential prognostic markers for survival and neurologic death in patients with breast cancer brain metastases who receive upfront SRS alone. J Radiosurg SBRT. 2018;5(4):277-283
Shenker, R. F., Hughes, R. T., McTyre, E. R., Lanier, C., Lo, H. W., Metheny-Barlow, L., Su, J., Thomas, A., Brown, D. R., Avery, T., Pasche, B., Cramer, C. K., Laxton, A. W., Tatter, S. B., Watabe, K., & Chan, M. D. (2018). Potential prognostic markers for survival and neurologic death in patients with breast cancer brain metastases who receive upfront SRS alone. Journal of radiosurgery and SBRT, 5(4), 277-283.
Shenker, Rachel F, et al. "Potential prognostic markers for survival and neurologic death in patients with breast cancer brain metastases who receive upfront SRS alone." Journal of radiosurgery and SBRT vol. 5,4 (2018): 277-283.
Shenker RF, Hughes RT, McTyre ER, Lanier C, Lo HW, Metheny-Barlow L, Su J, Thomas A, Brown DR, Avery T, Pasche B, Cramer CK, Laxton AW, Tatter SB, Watabe K, Chan MD. Potential prognostic markers for survival and neurologic death in patients with breast cancer brain metastases who receive upfront SRS alone. J Radiosurg SBRT. 2018;5(4):277-283. PMID: 30538888; PMCID: PMC6255726.
Copy Download .nbib Format: NLM
Share it on

J Radiosurg SBRT. 2018;5(4):277-283.

Potential prognostic markers for survival and neurologic death in patients with breast cancer brain metastases who receive upfront SRS alone.

Journal of radiosurgery and SBRT

Rachel F Shenker, Ryan T Hughes, Emory R McTyre, Claire Lanier, Hui-Wen Lo, Linda Metheny-Barlow, Jing Su, Alexandra Thomas, Doris R Brown, Tiffany Avery, Boris Pasche, Christina K Cramer, Adrian W Laxton, Stephen B Tatter, Kounosuke Watabe, Michael D Chan

Affiliations

  1. Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.
  2. Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.
  3. Department of Biostatistics, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.
  4. Department of Medicine (Hematology & Oncology), Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.
  5. Department of Neurosurgery, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.

PMID: 30538888 PMCID: PMC6255726

Abstract

PURPOSE/OBJECTIVES: Stereotactic radiosurgery (SRS) is used as a treatment option for breast cancer brain metastases. It is unclear what factors predict neurologic death for these patients.

MATERIALS/METHODS: A total of 128 patients with breast cancer brain metastases were treated with upfront SRS alone in this study. Survival was estimated using the Kaplan-Meier method. Clinicopathologic factors evaluated included age, ER/PR status, Her2 status, numbers of brain metastases treated, minimum SRS dose, disease-specific GPA, extracranial disease status and systemic disease burden.

RESULTS: ER or PR positivity was associated with a trend towards decreased neurologic death (subdistribution hazard ratio (sHR) = 0.54, p=0.06). Factors associated with non-neurologic death include extracranial disease status (sHR = 2.02, p=0.02) and dose (sHR = 1.11, p=0.02); Her2-positivity was associated with reduced hazard of non-neurologic death (sHR 0.52, p=0.05).

CONCLUSIONS: ER/PR positivity was associated with a trend towards less neurologic death. HER2 positivity was associated with a trend towards less non-neurologic death.

Keywords: brain metastases; breast cancer; breast cancer metastases; neurologic death; prognostic factors

Conflict of interest statement

Authors’ disclosure of potential conflicts of interest The authors have nothing to disclose.

References

  1. J Neurooncol. 2014 Oct;120(1):163-9 - PubMed
  2. Cancer. 2014 Feb 1;120(3):433-41 - PubMed
  3. J Clin Neurosci. 2015 Mar;22(3):561-5 - PubMed
  4. Neuro Oncol. 2017 Apr 1;19(4):558-566 - PubMed
  5. Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1008-1015 - PubMed
  6. Breast Cancer Res Treat. 2014 Aug;147(1):103-12 - PubMed
  7. Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):291-8 - PubMed
  8. J Clin Neurosci. 2017 Sep;43:6-10 - PubMed
  9. World Neurosurg. 2014 Dec;82(6):1250-5 - PubMed
  10. J Neurooncol. 2017 Nov;135(2):403-411 - PubMed
  11. J Neurooncol. 2012 Dec;110(3):381-8 - PubMed
  12. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2111-7 - PubMed
  13. Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):e53-9 - PubMed
  14. J Clin Oncol. 2012 Feb 1;30(4):419-25 - PubMed
  15. Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):131-141 - PubMed
  16. J Neurooncol. 2016 Mar;127(1):103-10 - PubMed
  17. J Neurosurg. 2011 Jun;114(6):1585-91 - PubMed
  18. Cancer. 2017 Jun 15;123(12):2283-2293 - PubMed
  19. Oncotarget. 2015 Aug 7;6(22):18945-55 - PubMed
  20. J Breast Cancer. 2013 Mar;16(1):122-6 - PubMed
  21. N Engl J Med. 1990 Feb 22;322(8):494-500 - PubMed
  22. J Med Imaging Radiat Oncol. 2012 Oct;56(5):554-60 - PubMed

Publication Types